Delivery Order SPE2DB22D3401-SPE2DB25FT2JQ

Award Date 3/3/25
Potential Completion Date 3/4/25
Potential Value $62K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML pharmaceuticals. The contract has a ceiling value of $49,514.00 and a performance period through April 15, 2024. This delivery order is issued under an indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, which has a potential value of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,021,744 units of the pharmaceutical product TYPHIM VI 25 MCG/0.5 ML VIAL 10ML. The contract, valued at $11,809.01, has a period of performance through March 21, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is part of a larger $999,999,999.00 indefinite delivery contract...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division for the provision of the pharmaceutical product TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML. The $1,319.92 firm-fixed-price contract has an ultimate completion date of May 31, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle...
This contract award, with a ceiling value of $12,730.51, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medical product "TYPHIM VI 25 MCG/0.5 ML VIAL 10ML" and has a period of performance through March 6, 2024. The contract is a firm fixed-price arrangement and was not set aside for any specific business category....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,830.91, is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a pharmaceutical product. The contract type is firm fixed price and the period of performance runs through May 2, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4566753874 TYPHIM VI 25 MCG/0.5 ML VIAL 10ML. The contract has a Firm Fixed Price, with a ceiling value of $14,526.62 and a period of performance through December 19, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026,...
This firm-fixed-price delivery order, valued at $14,981.12, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the government to efficiently procure a...
The federal government awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML in support of the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $81,663.67 and a period of performance through April 11, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which was not set aside. In addition,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML medical products. The contract has a ceiling value of $15,922.06 and an ultimate completion date of November 18, 2024. It is a Firm Fixed Price Delivery Order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a total ceiling value of $18,861.74 and a completion date of September 25, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the...
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT2JQ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML. The contract has a ceiling value of $62,156.88 and a period of performance through March 4, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/2/25, 9:46 AM